Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Seagen Inc. (SGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Seagen Phase 3 Trial of TUKYSA ® in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer"
08/02/2023 8-K Quarterly results
07/14/2023 8-K Quarterly results
06/01/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/31/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Seagen Stockholders Approve Acquisition by Pfizer"
05/23/2023 8-K Other Events  Interactive Data
05/15/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
04/27/2023 8-K Quarterly results
04/03/2023 8-K Other Events  Interactive Data
03/13/2023 8-K Investor presentation
Docs: "Agreement and Plan of Merger, by and among Seagen Inc., Pfizer Inc. and Aris Merger Sub, Inc",
"Voting Agreement, by and among Seagen Inc., Pfizer Inc., and Baker Bros. Advisors LP, on behalf of itself and certain specified persons identified therein in their respective capacities as record or beneficial owners of Seagen common stock",
"Form of Letter Agreement",
"Pfizer Invests $43 Billion to Battle Cancer",
"Investor Presentation"
01/19/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/18/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
08/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Seagen Statement on Outcome of Daiichi Sankyo Arbitration BOTHELL, Wash. — August 12, 2022 — Seagen Inc. today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract. “While we are disappointed with the arbitration decision, it was important for us to pursue this legal action,” said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. “This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four..."
07/28/2022 8-K Quarterly results
07/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Seagen and Astellas Announce Positive Topline Results For PADCEV ® with KEYTRUDA ® as First-Line Treatment for Advanced Urothelial Cancer"
06/01/2022 8-K/A Quarterly results
05/23/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/28/2022 8-K Quarterly results
Docs: "Seagen Reports First Quarter 2022 Financial Results"
04/15/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws of Seagen Inc"
04/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo"
03/11/2022 8-K Quarterly results
02/09/2022 8-K Quarterly results
Docs: "Seagen Reports Fourth Quarter and Full Year 2021 Financial Results"
10/28/2021 8-K Quarterly results
Docs: "Seagen Reports Third Quarter 2021 Financial Results"
09/21/2021 8-K Quarterly results
09/20/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK ™ in Previously Treated Recurrent or Metastatic Cervical Cancer"
08/09/2021 8-K Quarterly results
07/29/2021 8-K Quarterly results
Docs: "Seagen Reports Second Quarter 2021 Financial Results"
07/15/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
07/09/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"U.S. FDA Grants Regular Approval and Expands Indication for PADCEV ® for Patients with Locally Advanced or Metastatic Urothelial Cancer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy